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There has been a great and long-term concern that extended-spectrum b-lactamase (ESBL)/AmpC- and 
carbapenemase-producing Enterobacteriaceae occurring in animals may constitute a public-health issue. 
A large number of factors with complex interrelations contribute to the spread of those bacteria among 
animals and humans. ESBL/AmpC- or carbapenemase-encoding genes are most often located on mobile 
genetic elements favouring their dissemination. Some shared reservoirs of ESBL/AmpC or carbapenemase 
genes, plasmids or clones have been identiﬁed and suggest cross-transmissions. Even though exposure to 
animals is regarded as a risk factor, evidence for a direct transfer of ESBL/AmpC-producing bacteria from 
animals to humans through close contacts is limited. Nonetheless, the size of the commensal ESBL/AmpC 
reservoir in non-human sources is dramatically rising. This may constitute an indirect risk to public 
health by increasing the gene pool from which pathogenic bacteria can pick up ESBL/AmpC/carbapen-
emase genes. The extent to which food contributes to potential transmission of ESBL/AmpC producers to 
humans is also not well established. Overall, events leading to the occurrence of ESBL/AmpC- and 
carbapenemase-encoding genes in animals seem very much multifactorial. The impact of animal res-
ervoirs on human health still remains debatable and unclear; nonetheless, there are some examples of 
direct links that have been identiﬁed.
Introduction
Extended-spectrum b-lactamases (ESBL) and AmpC-producing
Enterobacteriaceae (EPE) have emerged globally in humans and
animals during the last decades, with the burning concern of ani-
mals being a possible source of ESBLs/AmpCs for humans. ESBL/
AmpC genes are mostly located on mobile genetic elements such as
plasmids, some of which are regarded as epidemic [1]. ESBL/AmpC
enzymes may signiﬁcantly differ in nature and prevalence between
animals and humans, which leads to uncertainties on the real
magnitude of their transfer from animals to humans [2]. Overall,
certain combinations of ESBL/AmpC genes and plasmids seem to
have more epidemiological success than others, and these
predominant combinations differ between animals and humans
[1]. Furthermore, some given Escherichia coli lineages play a major
role in the dissemination of ESBL/AmpC genes. In humans, a single
E. coli clone, namely the ST131, accounts for a large fraction of E. coli
infections and is frequently associated with the production of the
CTX-M-15 ESBL type. In contrast, ST131 has been poorly reported in
animals [3]. In fact, numerous data highlight the existence not only
of shared reservoirs of ESBL/AmpC genes between animals and
humans, but also of plasmids and clones, suggesting cross-
transmissions. However, studies showing direct transmission are
scarce [4,5], and ﬁnding identical resistance traits in different pla-
ces does not necessarily prove a causal relationship.
Carbapenemases are also important causes of resistance in
Enterobacteriaceae in humans, and carbapenemase genes are
associated with a high potential of dissemination [6]. The public
health risk related to carbapenemase-producing Enterobacteriaceae
(CPE) occurring in animals has been questioned on several occa-
sions [7,8]. Contrary to extended-spectrum cephalosporins (ESC),
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the use of carbapenems is highly limited in animals, which gives a
quite different epidemiological picture. Nonetheless, CPE in non-
human sources may constitute an underestimated reservoir sub-
sequently at risk to humans.
This review will discuss the threat to humans represented by
EPE/CPE found in animals or animal-derived food products. Wewill
consider the risk from both zoonotic and commensal perspectives
and analyse towhat extent the global data set on ESBL/AmpC genes,
plasmids and clones provides insight into the role of the food chain
as a relevant source of such resistant bacteria for humans.
Food-borne zoonotic pathogens as a source of ESBL/AmpC or
carbapenemases
The use of antibiotics in agriculture is considered a cause of
antimicrobial resistance selection in bacteria that may subse-
quently contaminate food products. In this respect, the use of ESC in
broilers has certainly contributed to the spread of ESBL/AmpC-
producing Salmonella enterica in the poultry sector [9]. Salmonella
enterica is one of the two most common causes of food-borne
gastroenteritis and can also induce invasive disease which may
require antimicrobial treatment with ESC. Since the ﬁrst reported
ESBL-producing S. enterica isolate in Tunisia in 1988 [10], ESBL
prevalence in this bacterial species has increased worldwide,
mostly in low-income countries. ESBL-producing S. enterica inges-
ted by consumers present an immediate risk for public health. A
series of serovars, including S. Enteritidis, S.Newport or S. Paratyphi
B, have been frequently recognized as ESBL or AmpC producers and
associated with poultry production. Human cases associated with
TEM-52-producing S. Infantis of poultry origin have been reported
in France and Belgium, and a CTX-M-1-producing S. Infantis has
recently been proved to cause human infections in Italy, most likely
through broiler meat [11]. Also, the blaCTX-M-1, blaCTX-M-15 and
blaCMY-2 genes were reported in human isolates of the S. Kentucky
ST198-X1-SGI1 clone, which has widely disseminated across
southern Asia, India, Africa and Europe in humans, food and various
animal species [12]. The role of imported foodstuffs as a source for
human exposure with ESBL-producing S. enterica has been hy-
pothesized. Indeed, the emergence of human andmeat isolates of S.
Newport, S. Agona and S. Anatum producing CTX-M-8 in Germany
might be related to food imported from Brazil where this enzyme
has been widely recognized, in contrast to Europe [13]. Prevalence
rates of ESBL-producing S. enterica in animals vary depending on
the countries and continents. A study conducted among 699
S. enterica isolates from 1152 retail chickens reported a 24.6% rate of
ESBL producers in Shanghai, China. Conversely, the overall preva-
lence of human infections with ESBL/AmpC-producing S. enterica in
Europe remains lowdaround 0.5% in two recent surveys conducted
on >20 000 isolates in Germany and the UK [14,15].
Carbapenemase production in S. enterica has been reported in a
limited number of human cases (Table 1). The ﬁrst carbapenemase-
producing S. enterica isolate was reported in 1998 in the USA. That
strain being of serotype Cubana actually produced the KPC-2
carbapenemase [16]. Later, NDM-1, OXA-48-like or KPC-like car-
bapenemases have been identiﬁed in different S. enterica serovars,
including S. Senftenberg, S.Westhampton, S. Stanley, S. Saintpaul, S.
Typhimurium and S. Kentucky ST198 (Table 1). At a global scale,
carbapenemase resistance in S. enterica is still rare, including in
countries where those enzymes are endemic. Most
carbapenemase-producing S. enterica reported in humans were not
reported to be associated with food sources; however, epidemio-
logical data were scarce for most cases. To date, only three studies
reported carbapenemase-producing S. enterica isolates directly
recovered from animals (Table 2). VIM-1 was reported in S. Infantis
in pig and poultry farms, ﬂies and rodents, and manure in Germany
[17]. An NDM-1-producing S. Corvallis isolate was recovered from a
black kite (Milvus migrans) in Germany [18], suggesting that occa-
sional vectors may be involved in the epidemiology of
carbapenemase-producing S. enterica. Very recently, IMP-4-
producing S. Typhimuriumwas reported from cats in Australia [19].
Shiga toxin-producing E. coli (STEC) are also among common
causes of food-borne gastroenteritis, but ESBLs have been associ-
ated with STEC in very few cases [20e24]. In 2011, a food-borne
outbreak likely associated with the consumption of fenugreek
sprouts in Germany was caused by a Shiga toxin-producing Entero-
Aggregative E. coli O104:H4 leading to 3817 human cases of bloody
diarrhoea and/or haemolyticeuraemic syndrome, of which 53were
fatal [25]. Incidentally, some E. coli O104:H4 isolates had also ac-
quired the blaCTX-M-15 gene, albeit without any consequence on the
clinical outcome. So far, no carbapenemase gene was identiﬁed in
STEC.
Overall, ESBL/AmpC-producing zoonotic pathogens contami-
nating food products constitute a direct risk for public health. In
those bacteria, ESBL/AmpC-encoding genes were most probably
acquired from the animal reservoir even though their exact origin is
difﬁcult to trace. The example of the O104:H4 E. coli epidemic is
interesting as the blaCTX-M-15 gene present in some strains was
located on an IncI1/ST31 plasmid also reported in other unrelated
animal/human contexts. It highlights our limited understanding of
the epidemiological distribution of speciﬁc ESBL genes/plasmids
Table 1
Carbapenemase-producing Salmonella enterica isolates from humans
Serovar Date of isolation Country Travel/hospitalization History Carbapenemase gene References
Senftenberg 2008 UK blaNDM-1 [78]
Senftenberg 2011 USA India blaNDM-1 [79]
Senftenberg 2011 USA India blaNDM-1 [80]
Agona ND Pakistan blaNDM-1 [81]
Agona 2012 Japan blaIMP-1 [82]
Westhampton 2012 France India blaNDM-1 [83]
Stanley 2012 China blaNDM-1 [84]
Senftenberg 2012 India blaNDM-1 [85]
Kentucky ST198 2010 Morocco blaVIM-2 [12]
Kentucky ST198 2009 Tunisia blaOXA-204 [86]
Kentucky ST198 2012 Lybia Transferred to Switzerland blaOXA-48 [87]
Kentucky ST198 2013 France Algeria blaOXA-48 [86]
Paratyphi B 2013 UK blaOXA-48 [78]
Typhimurium 2013 UK Africa blaOXA-48 [78]
Typhimurium 2013 Colombia blaKPC-2 [88]
Cubana 1998 USA blaKPC-2 [16]
Schwarzengrund 2013 Argentina blaKPC-2 [89]
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combinations in distinct settings. Noticeably, ESBL/AmpC encoding
genes in food-borne bacteria probably only represent the tip of the
iceberg with regard to the overall colonization rate of EPE in non-
human sources. To date, carbapenemase-producing S. enterica
poses a limited public health concern at a world scale.
Do contacts with animals enhance the risk of ESBL/AmpC
transfer to humans?
On-farm studies investigating the transfer of ESBL/AmpC pro-
ducers from food animals to workers are limited [4]. Such a transfer
is complex to elucidate because livestock and humans may harbour
identical ESBL/AmpC genes but located on different plasmids and/
or within different E. coli clones. Also, the ﬁnding of the same ESBL/
AmpC-producing clone in food animals and humans does not
necessarily prove a transfer as EPE are present in the farm envi-
ronment, which is a common source for animals and humans. In the
Netherlands, a cross-sectional study was conducted on 50 broiler
farms including 20 broilers per farm and 228 people in contact [5].
Multivariable modelling has considered numerous risk factors,
such as hours spent in the broiler house, performance of activities
in the farm or type of person, that were further investigated in
molecular studies on ESBL genes, plasmids and clones. In this study,
farmers and employees were at a higher risk of ESBL carriage than
partners and family members who had less contact. In addition, the
distribution of ESBL genes, plasmids and E. coli clones strongly
suggested a transfer of ESBL producers from broilers to humans.
Hence, occupational exposure should be regarded as a risk of ESBL
transfer from livestock to humans. However, more data are
required to quantitatively estimate the risk for humans related to
such situations.
Direct contact with pets may also be a source of ESBL/AmpC
genes for humans but evidence of transfers is even rarer than for
livestock. Some studies compared the resistance proﬁles and/or
clonal relationship of faecal isolates from dogs and owners, and
very few of them have focused on ESBL/AmpCs. Molecular simi-
larities among isolates from dogs and humans were found occa-
sionally [26], such as from dogs and humans living in the same
household. However the signiﬁcance of these data is difﬁcult to
infer at a larger scale, and the direction of the ESBL/AmpC transfer is
difﬁcult to prove [27]. To summarize, there is no convincing evi-
dence that pet ownership poses a higher risk to humans of
becoming colonized or infected with EPE.
Common ESBL/AmpC genes, plasmids and/or clones between
animals and humans
Numerous studies have compared the molecular features of
ESBL/AmpC genes, plasmids or clones between animal and human
sources [28e30]. Similarly to what is observed in humans, the most
frequent ESBL enzymes circulating in animals belong to the CTX-M
group [31]. In Asian countries, CTX-M-14 predominates in humans,
pets and poultry, whichmay possibly indicate cross-contamination,
but also a common third source. It is actually the only example
where such an ESBL enzyme is so uniformly distributed [2]. Indeed,
CTX-M-1 predominates in animals in Europe, but not in humans. In
contrast, CTX-M-15 is widely distributed in humans but poorly in
animals, with the notable exception of cattle [32]. A recent study in
Lebanese cattle proved an overrepresentation of CTX-M-15-
producing E. coli that were of different genetic backgrounds
(ST10, ST617, ST58, ST69) [33]. Noticeably, none of them belonged
to ST131, which is the most widespread in humans [3]. However,
non-ST131 CTX-M-15-producing E. coli were recently identiﬁed in
certain human subgroups, suggesting possible changes in the CTX-
M-15 epidemiology [34]. More globally, except for the ST131 E. coli
lineage, which seems to be associated with the human host, other
sequence types of CTX-M-producing E. coli, such as ST410, ST38 or
ST10, were found in human and animal sources [35,36]. Among
AmpC enzymes, CMY-2 is the predominant one in the animal
sector, mostly from poultry [2,37,38].
Other EPE were subjected to an animal/human comparison but
evidence of transfer was not obvious either. Exchanges of ESBL-
producing Klebsiella pneumoniae isolates between humans and
pets have been suggested, such as for the CTX-M-15-producing
ST15 K. pneumoniae clone widely disseminated in humans and
also recognized in pets and horses [39,40] or the human ST101
K. pneumoniae clone dominant in Italy also found as a CTX-M-15
producer in dogs [41]. However, a study conducted in Switzerland
showed that numerous ESBL-producing K. pneumoniae lineages
were associated with human infections, that were different from
Table 2
Carbapenemase-producing Enterobacteriaceae from animals
Bacterial species Animal species Date of isolation Country Carbapenemase gene References
Salmonella enterica Pig/poultry 2011 Germany blaVIM-1 [17]
Escherichia coli Pig/poultry 2011e2013 Germany blaVIM-1 [58e60]
Salmonella enterica Cat unknown Australia blaIMP-4 [19]
Diversea Silver gull 2012 Australia blaIMP-4 [64]
Salmonella enterica Black kite >2006 Germany blaNDM-1 [18,90]
E. coli Dog/cat 2008e2009 USA blaNDM-1 [61]
E. coli Pig 2014e2015 China blaNDM-1 [91]
E. coli Dog 2014e2015 Algeria blaNDM-5 [70,71]
E. coli Cow 2015 Algeria blaNDM-5 [72]
Klebsiella pneumoniae Cow 2015 China blaNDM-5 [76]
E. coli Poultry 2015 China blaNDM-5 Lv et al., poster ASM Microbe 2016
E. coli Poultry 2015 China blaNDM-5 [75]
E. coli Dog/cat 2015 China blaNDM-5 Sun et al., poster ASM Microbe 2016
E. coli Cow 2015 India blaNDM-5 [77]
K. pneumoniae/Klebsiella oxytoca Chicken meat 2013 Egypt blaNDM-type [63]
Diverseb Dog/cat/horse 2009e2011 Germany blaOXA-48 [65]
E. coli/K. pneumoniae Dog 2012 Germany blaOXA-48 [66]
E. coli Dog/cat 2009e2013 USA blaOXA-48 [67]
E. coli Dog 2015 France blaOXA-48 [68]
E. coli Chicken 2013 Lebanon blaOXA-48 [69]
E. coli Dog 2014e2015 Algeria blaOXA-48 [71]
a E. coli, Escherichia fergusonii, K. pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Kluyvera georgiana, Citrobacter freundii, Enterobacter cloacae, Proteus penneri, Cit-
robacter braakii.
b K. pneumoniae, Enterobacter cloacae.
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the DHA-producing ST11 K. pneumoniae clone in a veterinary
setting [42]. On the contrary, the CTX-M-15-producing ST114
Enterobacter cloacae clone recently reported as a high-risk clone in
humans was predominant in cats, dogs and horses [43]. Finally, a
common cluster of VEB-6-positive SGI1-V-carrying Proteus mir-
abilis isolates from humans, dog and turkey meat was identiﬁed in
Europe [44e46].
Many research groups compared ESBL/AmpC-producing E. coli
isolates and ESBL/AmpC genes from human and poultry sources
[4,5,29,30,47]. In a study, 19% of human isolates harbouring ESBL-
producing E. coli clones were identical to those found in chicken
meat, and 39% of the ESBL-positive chicken meat isolates belonged
to E. coli genotypes also found in human isolates [30], thereby
suggesting a clonal spread. Other clues sustaining exchanges of
ESBL/AmpC producers between poultry and humans result from
the comparison of ESBL-encoding plasmids, instead of focusing on
ESBL/AmpC genes or E. coli backgrounds [48]. Whole-genome
sequencing also reported similar IncI1/ST3 plasmids spreading
blaCTX-M-1 in unrelated humans and food animals [49]. The IncI1/
ST3 plasmid was also found in 83.3% of CTX-M-1-producing E. coli
in humans with closely related restriction proﬁles compared with
those found in animals [50]. Indistinguishable or closely related
IncN plasmids bearing blaCTX-M-1 were recovered from diverse
E. coli lineages of Danish pigs, pig farm employees and manure
samples [51].
All these studies investigated animal and human populations
that were not all necessarily in direct contact. In conclusion, most
epidemiological data were based on the comparison of molecular
features of ESBL/AmpC genes, plasmids or clonal backgrounds, and
so far limited information actually sustain clear transmission
pathways.
What is the ESBL/AmpC colonization rate of the non-human
reservoir?
The size of the ESBL/AmpC animal reservoir is a crucial question
with respect to risk assessment issues. Similarly to the situation in
humans, ESCs are widely used in animals and contribute to the
selection of ESBL/AmpC producers in that sector. Although re-
strictions on the use of ESCs in animals have mostly been set up in
Europe (Denmark, The Netherlands, France), numerous countries
outside Europe still have not implemented speciﬁc regulations.
International food trades are major driving forces for the transfer of
EPE within the food chaindand subsequently to human pop-
ulationsdso that ESC usage in a single country may result in high
rates of EPE in another country [52]. This has been clearly shown by
the spread of CMY-2-producing E. coli in the Swedish broiler pro-
duction pyramid next to the importation of top breeders carrying
the blaCMY-2 gene. Co-selection with other antibiotics than ESCs is
also an important driver as most ESBL/AmpC-producing bacteria
are multi-drug resistant. Altogether, the ESBL/AmpC prevalence is
inevitably rising worldwide in both animals and humans and,
consequently, so is the risk of cross-transmission.
There is evidence of increasing gut colonization with EPE in
animals, albeit depending on the countries and food sectors. In the
Netherlands, from the late 1990s to 2010, the proportion of ESBL-
Fig. 1. Geographical distribution of carbapenemase-producing Enterobacteriaceae reported in animals or animal-derived products according to the major carbapenemases families.
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producing E. coli has risen from 4% to 39% in calves [53]. The surface
contamination of food products with EPE has also been abundantly
reported, both from domestic and imported food, and mainly from
broiler meat [54,55]. EPE present on food are not necessarily of
animal origin as human handling is also a source of food contam-
ination. The risk to humans through food intake is also highly
dependent on whether those foodstuffs are consumed raw or not.
Yet, robust quantitative data are still lacking to conclude that there
is real enrichment of the human microbiota with ESBL/AmpC-
producing E. coli isolates via the food chain.
The burden of EPE in animals is also highlighted by the coloni-
zation of wild animals and remote environmental niches, which are
not supposed to be exposed to signiﬁcant amounts of antimicro-
bials. The number of studies reporting EPE in non-domestic animals
has been increasing, most of them focused on birds [56,57].
Considering the migratory behaviour of some birds, together with
the possibility of aquiring ESBL/AmpC-producing strains through
feeding on human wastes, farms, sewage or other contaminated
places, bird-related transmission is regarded as a potential threat
for spreading ESBL/AmpC-producing E. coli. Nonetheless, the
prevalence of those bacteria appears much lower inwildlife than in
farmed animals even though large population studies are still
limited. Further spatial and temporal investigations on the different
ESBL/AmpC-producing E. coli genetic backgrounds in wildlife are
also needed to clarify possible similarities with those of domestic
animals and humans. Finally, EPE have also been reported in veg-
etables, fruits or wastewater, meaning that the ESBL/AmpC burden
should be considered as a global and ecological pollution.
Carbapenemase producers in animals: a threat to humans?
Carbapenems are last-resort drugs to treat infections with
multidrug-resistant Gram-negative bacteria [6]. In veterinary
medicine, carbapenems have no legal indication and are not used in
routine practice, at least for food-producing animals. Position pa-
pers from the European Medicine Agency clearly stated that car-
bapenems should not be used in animal therapy. Subsequently, in
contrast to the human medicine, reports of carbapenemase pro-
ducers in animals are scarce.
The global distribution of the carbapenemase families reported
in animals is presented in Fig. 1. Carbapenemases in S. enterica in
humans and animals are presented above (Tables 1 and 2). How-
ever, VIM-1 was not only reported in S. Infantis but also in E. coli in
pig and poultry farms, along with their close environment [58,59]
(Fig. 2, Table 2). Of note, a recent retrospective study on those
positive pig farms in Germany showed that the VIM-1-producing
S. enterica and E. coli could persist over time in one single farm
[60]. CPE were also reported from companion animals (Fig. 2,
Table 2). NDM-1-producing E. coliwere reported from ﬁve dogs and
a cat in the USA [61] and from pigs in China [62], while NDM-type-
producing Klebsiella spp. were reported from retail chicken meat in
Egypt [63]. IMP-4-producing Enterobacteriaceae were found to be
highly prevalent in Australian gulls [64]. OXA-48-producing E. coli
and/or K. pneumoniae were isolated from dogs, cats and a horse in
Germany [65,66], the USA [67] and France [68] and from chicken in
Lebanon [69]. In Algeria, ﬁve carbapenemase-producing E. coliwere
detected in dogs, including four OXA-48- and a NDM-5-producing
Fig. 2. Geographical distribution of carbapenemase-producing Enterobacteriaceae reported in animals or animal-derived products according to the animal species/food fromwhich
they have been isolated.
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isolates that all co-expressed an ESBL enzyme. Of note, the same
NDM-5-producing ST1284 E. coli clone was found in a diseased dog
and inmilk andmilking cows [70e72]. The ﬁnding of NDM-5 in raw
milk in a country where local consumption is common highlights
the risk of direct transfer of NDM producers to humans in the
community. NDM-5 was also reported recently in milk and dairy
cows, poultry and dogs in China [73e76] and in cattle in India [77].
Both in Algeria and China, blaNDM-5 was located on the same IncX3-
type plasmid. Again, a selective pressure with carbapenems seems
unlikely in those animals, but domestic or food animals may act as
secondary reservoirs possibly re-circulating NDM producers back
to the human population.
Overall, the presence of CPE in animals is deﬁnitely worrying. At
this stage of knowledge, acquired carbapenemases in animals are
largely observational and most likely derived from human sources.
For instance, IMP-4 was found in cats and gulls in Australia, a
continent where IMP-4 is also the most common carbapenemase
reported in humans. Nonetheless, most carbapenemase reports in
animals resulted from side investigations within other studies and
do not reﬂect a large and systematic screening with appropriate
methods (using carbapenem-supplemented selective media, for
instance). Another point is that those genes are mostly located on
plasmids, which may carry other resistance genes such as tetracy-
clines, sulphonamides or phenicols widely used in veterinary
medicine. Once introduced in the animal sector, those plasmids
may be further co-selected and ampliﬁed by the use of other classes
of antibiotics before spreading back to humans.
Conclusion
The wide spread of EPE in numerous (if not all) settings of the
ecosphere highlights the current major scientiﬁc challenges to
combat those resistant bacteria in a One-Health approach. The use
of antibiotics in animals and humans is probably the main selective
factor responsible for the increasing prevalence rate of ESBL/
AmpCs, but many others should be considered, in particular the
role of international trades of food animals and products thereof. Of
note, other antimicrobials than ESC can select for EPE, such as
tetracyclines, sulphonamides and trimethoprim widely used in
animals, as many ESBL/AmpC genes are mostly located on plasmids
carrying a series of multidrug resistance genes. However, such an
alarming distribution of ESBL/AmpC genes does not necessarily
indicate a similar alarming risk of transfer to humans. The situation
with carbapenemases is quite different, most likely because of the
very limited use of carbapenems in animals. At this stage of
knowledge, CPE in animals should not be considered a major risk
for humans. However, even though the menace is still ahead of us,
the global recirculation of carbapenemase genes among animals
and humans may well create new and worrying epidemiological
pictures in the future.
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